Streamex Corp 8-K, filed Jun 22, 2021
Streamex Corp. (STEX)
About this 8-K
Streamex Corp filed this 8-K on June 22, 2021.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | | |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) | Identification No.) |
| | | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
|
N/A (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of exchange on which registered | ||
| | | The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On June 22, 2021, BioSig Technologies, Inc. (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that the data acquired by the PURE EP™ System would be featured in two presentations during the annual Heart Rhythm 2021 convention. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
|
99.1 |
Press Release, dated June 22, 2021 (furnished herewith pursuant to Item 7.01) |
|
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIOSIG TECHNOLOGIES, INC. |
|
|
Date: June 22, 2021 |
By: /s/ Kenneth L. Londoner Name: Kenneth L. Londoner Title: Executive Chairman |
Exhibit 99.1
BioSig’s Signal Processing System for Electrophysiology Featured in Two Clinical and Scientific Presentations during the annual Heart Rhythm 2021 convention
Abstracts are due to be presented by physician users and research investigators from two leading institutions
Westport, CT, June 22, 2021 /GLOBE NEWSWIRE/ — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the data acquired by the PURE EP™ System would be featured in two presentations during the annual Heart Rhythm 2021 convention.
The presentation titled “Post-Ablation Bipolar Voltage By PURE EP™ As a Marker Of Transmural Lesion,” co-authored by Pedram Kazemian, M.D. et al., of Deborah Heart and Lung Center in Browns Mills, New Jersey, will be held at 9:30 am ET on Thursday, July 29.
Later on the same day, the second abstract titled “Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude and Morphology During Radiofrequency Ablation,” co-authored by Jonathan Salas, B.S.; Pasquale Santangeli, M.D.; David Callans, M.D.; Francis E. Marchlinski, M.D.; Cory M. Tschabrunn, Ph.D. of University of Pennsylvania in Philadelphia, Pennsylvania, will be presented by Jonathan Salas, B.S. at 3:50 pm ET.
“We are honored that the global biomedical and scientific community has again recognized our latest clinical and research data. Our work with the medical centers of excellence is a significant part of our ongoing commitment to developing better treatments for complex heart rhythm disturbances. We look forward to further contributing our knowledge and expertise as we advance our clinical activities with the leading centers in the country,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.
The annual Heart Rhythm 2021 convention takes place on July 28-31, 2021, at the Boston Convention and Exhibition Center in Boston, MA. The Company will be exhibiting at booth 849. BioSig’s executive leadership, clinical, commercial, and engineering teams will host a series of presentations that will showcase the latest clinical data and demonstrate the newest software features of its PURE EP™ System, the non-invasive class II device that aims to drive procedural efficiency and efficacy in electrophysiology. In addition, the Company announced that it would host a series of events that will feature physician user presentations.
To date, 55 physicians have completed over 950 patient cases with the PURE EP™ System across nine clinical sites. The PURE EP™ System has been awarded FDA 510(k) clearance. The Company commenced a targeted commercial launch in 2020 and completed commercial sales to St. David’s HealthCare of Austin, Texas, an HCA Healthcare-owned hospital, and Mayo Foundation for Medical Education and Research.
About Heart Rhythm 2021
Heart Rhythm 2021 will convene over 600 finest clinicians, scientists, researchers, and innovators in the field of cardiac pacing and electrophysiology who will lead 100+ sessions about pacing, defibrillation, clinical arrhythmia management, ablation, pharmacology, genetics, basic science, health policy, and more.
The Heart Rhythm Society’s Annual Scientific Sessions is a Heart Rhythm Society program. Heart Rhythm Society (HRS) is a 501c3 international nonprofit organization with a mission to improve the care of patients by promoting research, education, and optimal health care policies and standards. Founded in 1979, HRS is a leading resource on cardiac pacing and electrophysiology. This specialty organization represents medical, allied health, and science professionals from more than 70 countries who specialize in cardiac rhythm disorders.
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, the PURE EP™ System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119